Eli Lilly pauses trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
A clinical trial of US-based drug manufacturer Eli Lilly & Co’s COVID-19 antibody treatment has been suspended following a reported safety concern. The drug, LY-CoV555, is undergoing a 10,000 participant government-sponsored study called ACTIV-3; an independent safety panel advised the pause. The antibody treatment is being tested in hospitalized COVID-19 patients, and in nursing homes to determine if it can prevent infection in those settings.
Published: October 13, 2020
Yahoo! FinanceRead Article